Pyrophosphate
Small molecule that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Asfotase alfaBoxed warning | Approved | AstraZeneca Pharmaceuticals | Protein or peptide | Hydrolytic enzymePyrophosphate hydrolytic enzyme | 4 |
| Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa | Asfotase alfa | Phase 3 | Active, not recruiting | Alexion Pharmaceuticals, Inc. | Oct 12, 2023 |
| Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa | Asfotase alfa | Phase 3 | Active, not recruiting | Alexion Pharmaceuticals, Inc. | Oct 12, 2023 |
| Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP | Asfotase alfa | Phase 3 | Active, not recruiting | Alexion Pharmaceuticals, Inc. | Oct 12, 2023 |
| A Prospective Sub-Study of the Global Hypophosphatasia Registry | Asfotase alfa | — | Recruiting | Alexion Pharmaceuticals, Inc. | Feb 10, 2022 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3545435, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets